
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing anti-cancer therapeutics using precision medicine. The company's main drug, Stenoparib, is currently in a Phase 2 clinical trial for the treatment of ovarian cancer and has shown promising results in extending overall survival for patients. The company's innovative DRP platform helps identify patients who are most likely to benefit from specific anti-cancer therapeutics, leading to a potential large market potential for ovarian cancer as well as PARP inhibitors. With a strong balance sheet and enough cash to sustain operations until 2028, the company has a positive outlook for long-term growth.
Bears say
Allarity Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of anti-cancer therapeutics for patients with high unmet medical needs. Their lead program, Stenoparib, has shown potential in treating advanced recurrent ovarian cancer, but the drug still faces significant development challenges and high risks. While Allarity has recently reported promising results and is targeting a strong market, there are concerns surrounding their balance sheet, liquidity, and potential competition. Despite these risks, the current valuation of the company presents an attractive buying opportunity with significant upside potential.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares